421 related articles for article (PubMed ID: 28049654)
1. Histone Lysine Demethylase Inhibitors.
Jambhekar A; Anastas JN; Shi Y
Cold Spring Harb Perspect Med; 2017 Jan; 7(1):. PubMed ID: 28049654
[TBL] [Abstract][Full Text] [Related]
2. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors.
Spannhoff A; Hauser AT; Heinke R; Sippl W; Jung M
ChemMedChem; 2009 Oct; 4(10):1568-82. PubMed ID: 19739196
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.
Lillico R; Stesco N; Khorshid Amhad T; Cortes C; Namaka MP; Lakowski TM
Future Med Chem; 2016 May; 8(8):879-97. PubMed ID: 27173004
[TBL] [Abstract][Full Text] [Related]
4. Targeting histone lysine methylation in cancer.
McGrath J; Trojer P
Pharmacol Ther; 2015 Jun; 150():1-22. PubMed ID: 25578037
[TBL] [Abstract][Full Text] [Related]
5. The role of histone demethylases in cancer therapy.
Hoffmann I; Roatsch M; Schmitt ML; Carlino L; Pippel M; Sippl W; Jung M
Mol Oncol; 2012 Dec; 6(6):683-703. PubMed ID: 22902149
[TBL] [Abstract][Full Text] [Related]
6. The future therapeutic potential of histone demethylases: A critical analysis.
Natoli G; Testa G; De Santa F
Curr Opin Drug Discov Devel; 2009 Sep; 12(5):607-15. PubMed ID: 19736620
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
Hosseini A; Minucci S
Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
[TBL] [Abstract][Full Text] [Related]
8. Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.
Li L; Li R; Wang Y
Bioorg Med Chem Lett; 2019 Feb; 29(4):544-548. PubMed ID: 30611617
[TBL] [Abstract][Full Text] [Related]
9. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Morera L; Lübbert M; Jung M
Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
[TBL] [Abstract][Full Text] [Related]
10. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
Kakizawa T; Ota Y; Itoh Y; Suzuki T
Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865
[TBL] [Abstract][Full Text] [Related]
11. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.
Willmann D; Lim S; Wetzel S; Metzger E; Jandausch A; Wilk W; Jung M; Forne I; Imhof A; Janzer A; Kirfel J; Waldmann H; Schüle R; Buettner R
Int J Cancer; 2012 Dec; 131(11):2704-9. PubMed ID: 22447389
[TBL] [Abstract][Full Text] [Related]
12. Targeting Histone Lysine Demethylase LSD1/KDM1A as a New Avenue for Cancer Therapy.
Fang Y; Liao G; Yu B
Curr Top Med Chem; 2019; 19(11):889-891. PubMed ID: 31389779
[No Abstract] [Full Text] [Related]
13. Advances and challenges in understanding histone demethylase biology.
Nowak RP; Tumber A; Johansson C; Che KH; Brennan P; Owen D; Oppermann U
Curr Opin Chem Biol; 2016 Aug; 33():151-9. PubMed ID: 27371875
[TBL] [Abstract][Full Text] [Related]
14. Assessing histone demethylase inhibitors in cells: lessons learned.
Hatch SB; Yapp C; Montenegro RC; Savitsky P; Gamble V; Tumber A; Ruda GF; Bavetsias V; Fedorov O; Atrash B; Raynaud F; Lanigan R; Carmichael L; Tomlin K; Burke R; Westaway SM; Brown JA; Prinjha RK; Martinez ED; Oppermann U; Schofield CJ; Bountra C; Kawamura A; Blagg J; Brennan PE; Rossanese O; Müller S
Epigenetics Chromatin; 2017; 10():9. PubMed ID: 28265301
[TBL] [Abstract][Full Text] [Related]
15. Advances in the development of histone lysine demethylase inhibitors.
Maes T; Carceller E; Salas J; Ortega A; Buesa C
Curr Opin Pharmacol; 2015 Aug; 23():52-60. PubMed ID: 26057211
[TBL] [Abstract][Full Text] [Related]
16. 3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.
Wu F; Zhou C; Yao Y; Wei L; Feng Z; Deng L; Song Y
J Med Chem; 2016 Jan; 59(1):253-263. PubMed ID: 26652247
[TBL] [Abstract][Full Text] [Related]
17. Trends of LSD1 inhibitors in viral infections.
Zwergel C; Stazi G; Mai A; Valente S
Future Med Chem; 2018 May; 10(10):1133-1136. PubMed ID: 29787289
[No Abstract] [Full Text] [Related]
18. Targeting Histone Methylation in Cancer.
McCabe MT; Mohammad HP; Barbash O; Kruger RG
Cancer J; 2017; 23(5):292-301. PubMed ID: 28926430
[TBL] [Abstract][Full Text] [Related]
19. Targeting histone demethylases as a potential cancer therapy (Review).
Diao W; Zheng J; Li Y; Wang J; Xu S
Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35801593
[TBL] [Abstract][Full Text] [Related]
20. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.
Schmitt ML; Hauser AT; Carlino L; Pippel M; Schulz-Fincke J; Metzger E; Willmann D; Yiu T; Barton M; Schüle R; Sippl W; Jung M
J Med Chem; 2013 Sep; 56(18):7334-42. PubMed ID: 24007511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
